Pieris Pharmaceuticals Appoints Jean-Pierre Bizzari, M.D., to its Board of Directors

19-May-2015 - Pieris Pharmaceuticals, Inc. announced that Jean-Pierre Bizzari, M.D. has joined the Company's Board bringing the total number of directors to six. Dr. Bizzari was the Executive Vice President, Group Head, Clinical Oncology Development at Celgene Corporation. Since joining Celgene in 2008, he ...

Pieris Pharmaceuticals and The University of Melbourne Receive Research Grant to Advance Immunological Diseases Program

01-Apr-2015 - Pieris Pharmaceuticals, Inc. (OTCQB:PIRS) and The University of Melbourne announced the receipt by the University of a research grant to further develop Pieris’ protein Anticalin®-brand therapeutic, PRS-060, in immunological diseases. The grant - which will support Pieris’ Australian subsidiary, ...

Pieris Initiates Phase I Clinical Trial for Anticalin® to Treat Anemia

15-Dec-2014 - Pieris AG announced the initiation of a Phase I clinical trial with PRS-080, an anti-hepcidin Anticalin® therapeutic protein designed to treat anemia. The trial is a placebo-controlled, single ascending dose evaluation of the compound’s safety and tolerability in healthy volunteers. Conducted in ...

Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics

26-Jun-2014 - Pieris AG announced that it has achieved a second milestone for its second program, and fifth milestone overall, in its discovery and development collaboration with Daiichi Sankyo Company Limited, triggering an undisclosed payment. The milestone is based on successful in vitro and in vivo studies ...

Pieris Receives Third Milestone Payment in Daiichi Sankyo Collaboration

20-Nov-2013 - Pieris AG has achieved its third milestone overall in its discovery and development collaboration with Daiichi Sankyo Company Limited, triggering an undisclosed payment, the company announced. The milestone, which is the first for the companies’ second collaborative program, was triggered by the ...

Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin Program

Grant Supports Personalized Anti-cancer Approach on Path to Clinic

09-Feb-2012 - Pieris AG announced the receipt of a EUR 1 million grant to support the development of the company’s proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and metastasis. The goal of the funded research will be to delineate a biomarker ...

EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia

Consortium Will Receive Six Million Euro from Seventh Framework Programme

25-Oct-2011 - The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and completing initial clinical development of a novel Anticalin® therapeutic. The project will be funded in large part by the European Commission Seventh ...

Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin PRS-080 Hepcidin Antagonist Drug Program

25-May-2011 - Pieris AG announced preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood. PRS-080 showcases Anticalins’ ability to encapsulate small targets like hepcidin ...

Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin Therapeutics

14-Apr-2011 - Pieris AG announced the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited under which Pieris will apply its proprietary Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets. Upon discovery and achievement by Pieris of ...

Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics

30-Sep-2010 - Pieris AG announced the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, under which Pieris will apply its proprietary Anticalin technology to discover novel Anticalin drugs against multiple targets, ...